Cargando…
Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19)
Lycopene is a group of phytochemicals found in nature, primarily in fruits and vegetables. Lycopene is thought to protect against a variety of diseases attributed to its antioxidant capabilities. Lycopene has anti-inflammatory, anti-cancer, and immunity-boosting qualities, among other biological and...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436159/ https://www.ncbi.nlm.nih.gov/pubmed/36050507 http://dx.doi.org/10.1007/s10787-022-01061-4 |
_version_ | 1784781301617786880 |
---|---|
author | Khongthaw, Banlambhabok Dulta, Kanika Chauhan, Pankaj Kumar Kumar, Vinod Ighalo, Joshua O. |
author_facet | Khongthaw, Banlambhabok Dulta, Kanika Chauhan, Pankaj Kumar Kumar, Vinod Ighalo, Joshua O. |
author_sort | Khongthaw, Banlambhabok |
collection | PubMed |
description | Lycopene is a group of phytochemicals found in nature, primarily in fruits and vegetables. Lycopene is thought to protect against a variety of diseases attributed to its antioxidant capabilities. Lycopene has anti-inflammatory, anti-cancer, and immunity-boosting qualities, among other biological and pharmacological benefits. COVID-19 (coronavirus disease 19) is an infectious disease caused by the SARS-CoV-2 virus, which has recently emerged as one of the world's leading causes of death. Patients may be asymptomatic or show signs of respiratory, cytokine release syndrome, gastrointestinal, or even multiple organ failure, all of which can lead to death. In COVID-19, inflammation, and cytokine storm are the key pathogenic mechanisms, according to SARS-CoV-2 infection symptoms. ARDS develops in some vulnerable hosts, which is accompanied by an inflammatory "cytokine syndrome" that causes lung damage. Immunological and inflammatory markers were linked to disease severity in mild and severe COVID-19 cases, implying that inflammatory markers, including IL-6, CRP, ESR, and PCT were significantly linked with COVID-19 severity. Patients with severe illness have reduced levels of several immune subsets, including CD4 + T, NK, and CD8 + cells. As a result, lycopene can be commended for bolstering physiological defenses against COVID-19 infections |
format | Online Article Text |
id | pubmed-9436159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-94361592022-09-02 Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19) Khongthaw, Banlambhabok Dulta, Kanika Chauhan, Pankaj Kumar Kumar, Vinod Ighalo, Joshua O. Inflammopharmacology Review Lycopene is a group of phytochemicals found in nature, primarily in fruits and vegetables. Lycopene is thought to protect against a variety of diseases attributed to its antioxidant capabilities. Lycopene has anti-inflammatory, anti-cancer, and immunity-boosting qualities, among other biological and pharmacological benefits. COVID-19 (coronavirus disease 19) is an infectious disease caused by the SARS-CoV-2 virus, which has recently emerged as one of the world's leading causes of death. Patients may be asymptomatic or show signs of respiratory, cytokine release syndrome, gastrointestinal, or even multiple organ failure, all of which can lead to death. In COVID-19, inflammation, and cytokine storm are the key pathogenic mechanisms, according to SARS-CoV-2 infection symptoms. ARDS develops in some vulnerable hosts, which is accompanied by an inflammatory "cytokine syndrome" that causes lung damage. Immunological and inflammatory markers were linked to disease severity in mild and severe COVID-19 cases, implying that inflammatory markers, including IL-6, CRP, ESR, and PCT were significantly linked with COVID-19 severity. Patients with severe illness have reduced levels of several immune subsets, including CD4 + T, NK, and CD8 + cells. As a result, lycopene can be commended for bolstering physiological defenses against COVID-19 infections Springer International Publishing 2022-09-01 2022 /pmc/articles/PMC9436159/ /pubmed/36050507 http://dx.doi.org/10.1007/s10787-022-01061-4 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Khongthaw, Banlambhabok Dulta, Kanika Chauhan, Pankaj Kumar Kumar, Vinod Ighalo, Joshua O. Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19) |
title | Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19) |
title_full | Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19) |
title_fullStr | Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19) |
title_full_unstemmed | Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19) |
title_short | Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19) |
title_sort | lycopene: a therapeutic strategy against coronavirus disease 19 (covid- 19) |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436159/ https://www.ncbi.nlm.nih.gov/pubmed/36050507 http://dx.doi.org/10.1007/s10787-022-01061-4 |
work_keys_str_mv | AT khongthawbanlambhabok lycopeneatherapeuticstrategyagainstcoronavirusdisease19covid19 AT dultakanika lycopeneatherapeuticstrategyagainstcoronavirusdisease19covid19 AT chauhanpankajkumar lycopeneatherapeuticstrategyagainstcoronavirusdisease19covid19 AT kumarvinod lycopeneatherapeuticstrategyagainstcoronavirusdisease19covid19 AT ighalojoshuao lycopeneatherapeuticstrategyagainstcoronavirusdisease19covid19 |